Sponsor a Study
with AXCES

The populations of the Southwest are unique, we know how to reach them.

75+

Combined years of research experience on our staff

130+

Clinical trials completed

70%

Percentage of staff who are bilingual

Several chile ristras hang from wooden posts on a porch of an adobe house with a turquoise door.

Our Populations Are Uniquely Diverse…

US

NM

Hispanic or Latino

American Indian/Alaskan Native

White (not Hispanic or Latino)

18.9%

1.3%

59.3%

50.1%

11.2%

35.9%

A diverse group of people of all ages pose for a photo on a porch in front of a white front door.

…So Are Our Trials

Despite clinical trials’ history of being non-diverse, we have always prioritized diversity, ensuring that every community is represented in our data. To date, our trials have been:

>64% Female

>56% Hispanic/Latino

>11% Native American

In addition, we received Exemplary scores in every category on the SCRS Diversity Site Assessment and are always looking to improve them:

143/150 Overall

58/60 Site Overview

50/54 Recruitment and Outreach

35/36 Patient-Focused Services

AXCES Is Committed to Diversity, Access, Equity, & Representation

We have always believed that participants in clinical trials must represent New Mexico’s diverse communities, especially those who have historically been excluded from clinical research. This includes but is not limited to:

  • communities of color

  • diverse nationalities

  • cis and transgender women

  • individuals who identify as LGBTQIA+

  • those who identify as gender diverse

  • individuals who do not live in urban centers

We are also committed to increasing access to marginalized communities, including those who use substances, are unhoused, or are struggling with mental and behavioral health issues.

We do all of this in an affirming, stigma-free environment.   

Current & Previous Partners

5 rounded horizontal lines of varying length stacked on top of each other. To the left in 2 shades of blue are the letters I,Q,V,I,A.
Merck logo
Gray rectangle with the right side coming to a point. In the rectangle in white in all caps are the letters N,I,H. To the right in gray, it reads, "National Institute of Allergy and Infectious Diseases."
2 lines in light and dark blue that look like ribbons curving around something. To the left in dark blue is the word Pfizer.
The letters P,P,D in purple in italic all caps with a tiny registered symbol to right of the top of the D.
The word Regeneron in italic all caps in a medium blue.
Roche logo
VIR logo
Red and white simple icon of a leaf over a shield. To the left in gray is the word Gilead in all caps.
Abbvie logo
The company name Icon in white in all caps in a rounded font. A teal green circle surrounds each letter.
Bright orange square with rounded corners except the top right, which is pointy. In the middle in all caps are the letters G,S,K in a futuristic font.

Capabilities & Experience

  • -Phase I-IV Clinical Trials
    -PBMC processing
    -Intense pharmacokinetic (PK) studies
    -Airborne infectious diseases
    -IV infusion
    -Diagnostic devices

  • -Dedicated exam spaces with infusion capabilities
    -Refrigerators, -20 freezers, and -80 freezers that are monitored electronically 24-hours a day
    -Refrigerated centrifuges, microscopes, pipettors, and all necessary technical supplies to process and package biologic specimens
    -Double locked pharmacy spaces for IP storage and preparation with the ability to segregate IP for blinded and unblinded staff
    -Emergency kits and AEDs
    -Alarm system and other security measures

  • Our staff is heavily experienced in Phase I-IV studies with an emphasis on Pharmacokinetics (PK), Intense PK, and PBMC processing.

    We have participated in pharmaceutical-company-sponsored, investigator-initiated, and government-funded clinical trials.

    Our team has experience with clinical trials in the following areas:

    -HIV treatment and prevention
    -HIV-associated conditions (lipodystrophy, lipoatrophy, peripheral neuropathy, CNS side effects)
    -Liver disease (hepatitis B&C, NASH/fatty liver disease)
    -Sexually transmitted infections
    -Cancer screening (high resolution anoscopy for anal cancer)
    -Vaccines
    -Pharmacogenomics
    -Monoclonal antibodies
    -Immunology
    -COVID
    -Genetics  
    -Population health related to harm reduction and adverse childhood events

  • Each location conducting COVID treatment and vaccine clinical trials are equipped with negative pressure air filtration and a separate "COVID bubble" for subjects with active COVID or other aerosolized infectious diseases.

Current and Previous Trials Conducted at AXCES

    • GS-US-0536-5939 Phase 2 Long-Acting HIV Treatment

    • VH209639 EMBRACE Phase 2b Long-Acting HIV Treatment

    • GS-US-544-5905 Phase 1b HIV Naive Treatment

    • Toolbox 1518 Respiratory Device

    • AK-US-001-0105 Phase 3 NASH/MASH Treatment

    • GS-US-621-6289 Phase 2 HIV treatment

    • GS-US-563-6041 Phase 2 HIV treatment

    • GS-US-536-5816 Phase 1b HIV treatment

    • Merck-V116-005 Phase 3 Pneumococcal Vaccine

    • Merck-V116-004 Phase 3 Pneumococcal Vaccine

    • Merck-V110-911 Phase 3 COVID-19 Vaccine with Pneumococcal Vaccine

    • Roche LIA-COV-560 COVID-19 Diagnostics

    • C4671006 Phase 3 COVID-19 prophylaxis

    • C4671002 Phase 3 COVID-19 treatment

    • MK4482-013 Phase 3 COVID-19 prophylaxis

    • MK4482-002 Phase 3 COVID-19 treatment

    • Regeneron -R14256-COV-2149-COVID-19 treatment

    • ACTIV-2 Phase 2/3 COVID-19 treatment

    • Regeneron R10933-10987-COV-2067 Phase 3 COVID-19 treatment

    • VIR 7831-5001 Phase 3 COVID-19 treatment

    • Gilead GS-US-540-9012 Phase 3 COVID-19 treatment

WE’D LOVE TO TALK ABOUT YOUR NEXT TRIAL!

Tell us more about your upcoming study so we can discuss how we can partner with you to recruit diverse participants. Call us at 505-207-8078, email us at info@axcesresearch.com, or fill out the form below, and we’ll be in touch as soon as possible.